title: [A case of tuberculous peritonitis developed during chemotherapy for tuberculous pleurisy as paradoxical response].
abstract: After the start of anti-tuberculous treatment, paradoxical worsening of tuberculous lesions has been described. However, abdominal tuberculosis as paradoxical response is relatively rare. This report describes the 26-year-old female who suffered from peritoneal tuberculosis while treating tuberculous pleurisy with anti-tuberculous medications. It was considered as paradoxical response, rather than treatment failure or else. She was successfully managed with continuing initial anti-tuberculous medications. When a patient on anti-tuberculous medications is presented with abdominal symptoms, the possibility of paradoxical response should be considered to avoid unnecessary tests and treatments, which may result in more suffering of the patient. Herein, we report a case of peritoneal tuberculosis as paradoxical response while treating tuberculous pleurisy.
authors.affiliation: Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Kim
authors.forename: Tae Hoon
authors.initials: TH
authors.lastname: Oh
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Seo
authors.forename: Jin Hee
authors.initials: JH
authors.lastname: Hong
authors.forename: Tae Joo
authors.initials: TJ
authors.lastname: Jeon
authors.forename: Dong Dae
authors.initials: DD
authors.lastname: Seo
authors.forename: Won Chang
authors.initials: WC
authors.lastname: Shin
authors.forename: Won Choong
authors.initials: WC
authors.lastname: Choi
mesh_terms: D000243:Adenosine Deaminase / Q000032:analysis; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects / Q000627:therapeutic use; D014395:Peritonitis, Tuberculous / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D010996:Pleural Effusion / Q000139:chemically induced; D011718:Pyrazinamide / Q000009:adverse effects / Q000627:therapeutic use; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D014396:Tuberculosis, Pleural / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000188:drug therapy
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D004977:Ethambutol; D000243:Adenosine Deaminase; D007538:Isoniazid; D012293:Rifampin